Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Gains from Investment Securities: 2020-2025

Historic Gains from Investment Securities for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $6.7 million.

  • Apellis Pharmaceuticals' Gains from Investment Securities rose 3084.89% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 million, marking a year-over-year increase of 77.66%. This contributed to the annual value of $8.0 million for FY2024, which is 7.11% down from last year.
  • According to the latest figures from Q3 2025, Apellis Pharmaceuticals' Gains from Investment Securities is $6.7 million, which was up 11,109.84% from -$61,000 recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Gains from Investment Securities ranged from a high of $9.2 million in Q2 2021 and a low of -$15.6 million during Q1 2022.
  • For the 3-year period, Apellis Pharmaceuticals' Gains from Investment Securities averaged around -$540,727, with its median value being -$61,000 (2025).
  • Within the past 5 years, the most significant YoY rise in Apellis Pharmaceuticals' Gains from Investment Securities was 671,300.00% (2021), while the steepest drop was 2,696.96% (2021).
  • Over the past 5 years, Apellis Pharmaceuticals' Gains from Investment Securities (Quarterly) stood at $8.8 million in 2021, then plummeted by 118.18% to -$1.6 million in 2022, then soared by 293.83% to $3.1 million in 2023, then plummeted by 125.27% to -$786,000 in 2024, then soared by 3,084.89% to $6.7 million in 2025.
  • Its Gains from Investment Securities stands at $6.7 million for Q3 2025, versus -$61,000 for Q2 2025 and -$198,000 for Q1 2025.